News Releases

Date	Title and Summary	View
May 17, 2022	KalVista Pharmaceuticals Announces Non-Proprietary Name Selection for KVD900 – “Sebetralstat” Approved by WHO and USAN – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 17, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease...	Additional Formats PDF Version
April 11, 2022	KalVista Pharmaceuticals to Present at 21st Annual Needham Virtual Healthcare Conference CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Apr. 11, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will be...	Additional Formats PDF Version
April 4, 2022	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Apr. 4, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate of 7,000 shares of...	Additional Formats PDF Version
March 22, 2022	KalVista Announces Publication of Additional KVD900 Data in Clinical & Experimental Allergy CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Mar. 22, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the publication...	Additional Formats PDF Version
March 10, 2022	KalVista Pharmaceuticals Reports Third Fiscal Quarter Results – KVD900 Phase 3 KONFIDENT Trial Initiated – – KVD824 Phase 2 KOMPLETE Clinical Trial Enrollment on Track – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Mar. 10, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery,...	Additional Formats PDF Version
March 7, 2022	KalVista Pharmaceuticals Announces Initiation of KVD900 Phase 3 KONFIDENT Clinical Trial -KONFIDENT to Evaluate KVD900 As First Oral On-Demand Therapy for HAE- -KONFIDENT Designed to Support Broad Label for Treatment of All HAE Attacks- CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Mar. 7, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical...	Additional Formats PDF Version
March 3, 2022	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Mar. 3, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate of 5,000 shares of...	Additional Formats PDF Version
February 28, 2022	KalVista Pharmaceuticals Presents Data Showing Rapid Reduction of Plasma Kallikrein Activity After Oral KVD900 Treatment and Early Symptom Relief From HAE Attacks in Patients – KVD900 Phase 2 data presented at the American Academy of Allergy , Asthma & Immunology (AAAAI) Annual Scientific Meeting – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 28, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the...	Additional Formats PDF Version
February 3, 2022	KalVista Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 3, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced it will participate in a...	Additional Formats PDF Version
February 2, 2022	KalVista Pharmaceuticals to Present Data on Oral On-Demand HAE Therapy KVD900 at AAAAI 2022 CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 2, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that new data on...	Additional Formats PDF Version